# KAND567 Versus Placebo in Subjects Hospitalized With COVID-19

> **NCT06012565** · PHASE2 · TERMINATED · sponsor: **Novakand Pharma AB** · enrollment: 35 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** KAND567
- **DRUG:** Microcrystalline cellulose

## Key facts

- **NCT ID:** NCT06012565
- **Lead sponsor:** Novakand Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-11
- **Primary completion:** 2021-08-07
- **Final completion:** 2021-08-07
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06012565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06012565, "KAND567 Versus Placebo in Subjects Hospitalized With COVID-19". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06012565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*